The development of new angiotensin II receptor vaccine
Project/Area Number |
25870715
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Kidney internal medicine
Immunology
|
Research Institution | Keio University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | 高血圧 / アンジオテンシン / ワクチン / 粘膜免疫 |
Outline of Final Research Achievements |
To develop the new treatment for hypertension, that improves medical adherence, I focused on the vaccine strategy. To avoid the injection-related pain and skin adverse events, I aimed to create a new non-injectable anti-hypertensive vaccine. For the development of oral anti-hypertensive vaccine, the expression vector which angiotensin II type 1 receptor (AT1) - Cholera toxin B subunit(CTB) chimeric sequence was inserted into was used to transformed the rice. Although resultant transgenic rice seeds expressed AT1-CTB protein, its immunogenicity to AT1 was poor. For the development of nasal vaccine, AT1 partial peptide was synthesized and conjugated with pneumococcal surface protein A (PspA). AT1-PspA antigen was mixed with adjuvant and incorprated into nanogels. Intranasal immunization with AT1-PspA vaccine induced AT1-specific serum IgG antibody and also lower blood pressure in the spountaneously hypertensive rats.
|
Report
(4 results)
Research Products
(2 results)
-
[Presentation] 経鼻投与型高血圧ワクチンの開発研究2015
Author(s)
畔上達彦、篠村裕之、林香、中村真理、伊藤裕
Organizer
第51回高血圧関連疾患モデル学会学術総会
Place of Presentation
千里ライフサイエンスセンター(大阪府豊中市)
Year and Date
2015-10-30
Related Report
-